01 — At a Glance
The Company That Sold You Cough Syrup But Forgot to Taste It
- Q3 FY26 Revenue₹349 Cr
- Q3 FY26 PAT-₹10.7 Cr
- Q3 FY26 EPS-₹4.82
- TTM Revenue₹1,255 Cr
- TTM PAT-₹12.4 Cr
- Book Value / Share₹347
- Price to Book1.32x
- ROCE6.01%
- ROE (TTM)0.05%
- Debt/Equity0.51x
The Real Headline: Solara’s Q3 delivered ₹349 crore revenue — solid +16% YoY — but a ₹10.7 crore loss that somehow made CRISIL “revise the outlook to Stable.” The stock has returned -21% in 3 months, -28% in 6 months, and -19% in 5 years. The company lost ₹12.4 crores in TTM. And management just held a conference call admitting their entire ibuprofen business is “broken.” But let’s talk about “strategic optionality,” shall we?
02 — Introduction
An API Maker That Specializes in Making Losses Instead
Let me set the scene. You’re a pharmaceutical company. You need Active Pharmaceutical Ingredients — the actual medicine molecules that go into pills. You can’t make them yourself. So you call Solara. They’ve been making APIs since 2017, when they were spun out as a “pure play” from Strides Shasun. They own six globally compliant facilities. They sell to 73+ countries. On paper, they’re the Indian API player the industry has been waiting for.
Except — and this is becoming harder to ignore — Solara has lost money in more quarters than it has made it. TTM PAT is -₹12.4 crores. FY24 PAT was a catastrophic -₹567 crores. The stock peaked at ₹734 in early 2025 and has given back 37% since. The company has raised ₹450 crores through a rights issue, cut debt, and hired external advisors to “evaluate the ibuprofen business.” This is financial news speak for: “We have a big broken asset and we don’t know what to do with it.”
Here’s the thing: Solara makes two types of APIs. The “growth API” business (non-ibuprofen and derivatives) is reportedly “class-leading” with 56% gross margins and 25% EBITDA. But the plain ibuprofen business — which consumes manufacturing space, borrows capital, and drowns every quarter in red ink — is tanking the consolidated numbers. The Feb 2026 concall was management essentially admitting they have a “dated” process, 10,000+ tons of capacity for a 3,000-ton utilization, and big customers who won’t let them fix the technology because regulatory change is expensive. Welcome to business, but worse.
CRISIL Rating (Apr 2025): Revised outlook to Stable from Negative. Ratings at Crisil BBB/Stable (LT) and Crisil A3+ (ST). Translation: “We believe this is a temporary operational issue, not a solvency crisis. Proceed with cautious optimism, but don’t say we didn’t warn you if the advisor recommends selling the plant.”
03 — Business Model: APIs and Regrets
They Make the Molecules. Just Not Very Profitably.
Members get full access to every article.
